Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services

Accula COVID-19 Point-of-care Test

ASPR’s Portfolio of COVID-19 Medical Countermeasures under EUA

BARDA is supporting the development of Mesa Biotech International’s Accula COVID-19 test, a rapid molecular (RT-PCR), visually-read test that detects SARS-CoV-2 RNA in combined throat and nasal swab samples in 30 minutes. The platform is small, portable, and battery-operated and is suitable for use in point-of-care settings.  To learn more, see the award announcement.

Emergency Use Authorization

On March 23, 2020, FDA issued an Emergency Use Authorization (EUA) to allow Mesa Biotech’s Accula COVID-19 point-of-care test to be used to diagnose COVID-19.


  • This page last reviewed: May 21, 2020